NCT05133414Completed
Subclavian Ansae Stimulation in AF (SAS-AF)
Effects of Selective Left Subclavian Ansae Stimulation on Human Cardiac Electrophysiological Properties - a Potential Percutaneous Target for Neuromodulation in Atrial Fibrillation.
Source: ClinicalTrials.gov · Last updated 19 Jan 2024
Brief summary (registry, in English)
Atrial Fibrillation (AF) is a common heart rhythm condition that affects over 3% of the total population. AF can lead to serious health problems such as heart failure or stroke and can also cause troublesome symptoms in some people. Although many advances have been made, there remains a pressing need to improvement treatment of AF. It is increasingly recognised that the brain and nerves can influence the electrical activity of the heart. Therefore, this research involves studying a new nerve target (Subclavian ansae) that is connected to the heart and can be a potential target for future treatment of AF. This nerve lies around an area close to an artery that runs to participant's left arm called left subclavian artery which can be approached via leg (key hole). The investigators aim to conduct this study in patients who have been referred for first time AF ablation.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 1 Nov 2021
- Start date
- 5 Jul 2022
- Primary completion date
- 8 Dec 2023
- Lead sponsor
- Barts & The London NHS Trust
- Diseases
- Atrial fibrillation
- NCT number
- NCT05133414
What you commit to
- Study type: Interventional
- Participants enrolled: 20
- From 5 Jul 2022 to the primary completion date, 8 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Uncontrolled hypertension
- Recent Stroke/ myocardial infarction
- Significant carotid artery stenosis or peripheral arterial disease
- Allergy to contrast
Lab values
- Creatinine clearance (eGFR) \< 30mls/min
Other
- Contraindication or unable to take anticoagulation
- Contraindication for catheter ablation
- BMI \> 35
- Haemodynamically unstable
- Significant carotid artery stenosis
- Presence of pacemaker or implantable cardioverter defibrillator (ICD)
Who the study is looking for
- Ability to give informed consent
- Age 18-80 years
- First time PAF ablation
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Barts Heart Centre Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.